Trimel Pharmaceuticals Corporation
TSX : TRL

Trimel Pharmaceuticals Corporation

April 30, 2013 17:50 ET

Trimel Pharmaceuticals Corporation Announces Appointment of New Director

TORONTO, ONTARIO--(Marketwired - April 30, 2013) - Trimel Pharmaceuticals Corporation (TSX:TRL) is pleased to announce the appointment of Dr. Lorne Tyrrell to its Board of Directors.

Dr. Tyrrell has had a distinguished medical career, with numerous research achievements particularly in the field of virology and antiviral research. Dr. Tyrrell is presently a professor in the Department of Medical Microbiology and Immunology at the University of Alberta Faculty of Medicine and Dentistry and is a founding director of the Li Ka Shing Institute of Virology at the University of Alberta. Dr. Tyrrell is a recipient of over forty awards and honours, including the Order of Canada and Alberta Order of Excellence, and is a member of the Canadian Medical Hall of Fame. Additionally, Dr. Tyrrell has been active in numerous business ventures in the pharmaceutical industry and has previously served, or is currently serving, on the boards of directors of other publicly traded companies.

"The addition of Dr. Tyrrell to the Board of Directors is a very positive event for Trimel," said Bruce Brydon, Chairman of the Board. "With his long and esteemed career in medical research and deep pool of scientific knowledge, we believe he is an excellent addition to the Board and will help to further Trimel's development and growth. We are extremely excited to move forward with Dr. Tyrrell as part of the Board."

About Trimel

Trimel is a specialty pharmaceutical company actively developing medications for male hypogonadism, female sexual dysfunction and various respiratory disorders. CompleoTRT™, a product utilizing Trimel's licensed bioadhesive intranasal gel technology, has been filed with the FDA for regulatory approval in the United States. For more information, please visit www.trimelpharmaceuticals.com.

Contact Information